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Introduction: Secondary osteoporosis is common in systemic lupus erythematosus and leads to a reduction in
quality of life due to fragility fractures, even in patients with improvement of the primary disorder. Systemic
transplantation of mesenchymal stem cells could ameliorate bone loss and autoimmune disorders in a MRL/lpr
mouse systemic lupus erythematosus model, but the detailed therapeutic mechanism of bone regeneration is not
fully understood. In this study, we transplanted human bone marrow mesenchymal stem cells (BMMSCs) and stem
cells from exfoliated deciduous teeth (SHED) into MRL/lpr mice and explored their therapeutic mechanisms in
secondary osteoporotic disorders of the systemic lupus erythematosus model mice.
Methods: The effects of systemic human mesenchymal stem cell transplantation on bone loss of MRL/lpr mice
were analyzed in vivo and ex vivo. After systemic human mesenchymal stem cell transplantation, recipient BMMSC
functions of MRL/lpr mice were assessed for aspects of stemness, osteogenesis and osteoclastogenesis, and a series
of co-culture experiments under osteogenic or osteoclastogenic inductions were performed to examine the efficacy
of interleukin (IL)-17-impaired recipient BMMSCs in the bone marrow of MRL/lpr mice.
Results: Systemic transplantation of human BMMSCs and SHED recovered the reduction in bone density and
structure in MRL/lpr mice. To explore the mechanism, we found that impaired recipient BMMSCs mediated the
negative bone metabolic turnover by enhanced osteoclastogenesis and suppressed osteoblastogenesis in secondary
osteoporosis of MRL/lpr mice. Moreover, IL-17-dependent hyperimmune conditions in the recipient bone marrow of
MRL/lpr mice damaged recipient BMMSCs to suppress osteoblast capacity and accelerate osteoclast induction. To
overcome the abnormal bone metabolism, systemic transplantation of human BMMSCs and SHED into MRL/lpr mice
improved the functionally impaired recipient BMMSCs through IL-17 suppression in the recipient bone marrow and
then maintained a regular positive bone metabolism via the balance of osteoblasts and osteoclasts.
Conclusions: These findings indicate that IL-17 and recipient BMMSCs might be a therapeutic target for secondary
osteoporosis in systemic lupus erythematosus.* Correspondence: yamazata@dent.kyushu-u.ac.jp
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Osteoporosis is defined as a reduction in bone strength
and is the most common bone disease [1]. The bone loss
is primarily related to age and/or menopause and sec-
ondarily affected by underlying risk factors such as nu-
tritional deficiencies, diseases, or drugs [2]. Systemic
lupus erythematosus (SLE) is a refractory and chronic
multiorgan autoimmune disease. Because recent medical
advances have successfully increased the lifespan of pa-
tients with SLE, many clinical researchers have focused
on the organ damage associated with the systemic
chronic inflammation and/or long-term medications re-
lating to quality of life [3]. Secondary osteoporosis fre-
quently occurs in SLE patients, which causes fragility
fractures [4]. Currently, there are no safe or efficient
treatments for SLE-associated osteoporosis.
Mesenchymal stem cells (MSCs) are a typical type of
adult stem cell with the capabilities of self-renewal and
multilineage differentiation [5]. Recent studies show that
MSCs have immunomodulatory effects on immune cells
[6, 7], and MSC-based cell therapy has been greatly fo-
cused on the treatment of various immune diseases such
as acute graft-versus-host disease [8] and inflammatory
bowel disease [9]. Previous allogeneic transplantation of
human bone marrow MSCs (hBMMSCs) and human
umbilical cord-derived MSCs (hUCMSCs) governs suc-
cessful therapeutic efficacy in refractory SLE patients
[10–12]. However, it is unclear whether MSC transplant-
ation is an effective treatment for skeletal disorders in
SLE patients.
MRL/lpr mice are a well-known model of human SLE-
like disorders with clinical manifestations including a
short lifespan, abundant autoantibodies, glomeruloneph-
ritis, and a breakdown of self-tolerance [13]. Further-
more, MRL/lpr mice exhibit a severe reduction of the
trabecular bone, which is associated with excessive
osteoclastic bone resorption and limited osteoblastic
bone formation [10]. Recent studies show that systemic
transplantation of human MSCs, including hBMMSCs,
hUCMSCs, stem cells from human exfoliated deciduous
teeth (SHED), and human supernumerary tooth-derived
stem cells, improves primary autoimmune disorders in
MRL/lpr mice, such as elevated autoimmune antibodies,
renal dysfunction, and abnormal immunity [14–18]. In
addition, hBMMSC and SHED transplantation markedly
recovers the bone loss in MRL/lpr mice [16, 17]. These
results indicate that MSC transplantation might be a
therapeutic approach for SLE patients who suffer from
secondary osteoporosis. However, little is known about
the human MSC-mediated therapeutic mechanism in
the skeletal disorder of MRL/lpr mice.
Osteoporosis is characterized by a disruption of the
balance between the formation and resorption of bone,
which is associated with abnormal development ofosteoclasts and osteoblasts. Increasing evidence has
shown that BMMSCs from SLE patients and SLE model
MRL/lpr mice exhibit a reduction in their bone-forming
capacity both in vitro and in vivo [10, 19]. Therefore, the
osteogenic deficiency of recipient BMMSCs might ex-
plain the origin of osteoporosis in SLE. Accordingly, the
impaired BMMSCs might be a therapeutic target for
osteoporosis. However, little is known about the pro-
cesses through which recipient BMMSCs are damaged
functionally or the underlying mechanism of human
MSC transplantation in restoration of the reduced bone
formation via recipient BMMSCs in the bone marrow
under SLE conditions.
In this study, we used MRL/lpr mice to examine the
therapeutic efficacy and mechanisms of systemically
transplanted hBMMSCs and SHED in the secondary
osteoporotic disorders of SLE. Moreover, we focused on
the pathological and clinical contributions of recipient
BMMSCs to the dysregulation of bone metabolism
through osteoblasts and osteoclasts in the inflammatory
bone disorder of SLE.
Materials and methods
Human subjects
Human exfoliated deciduous teeth were obtained as
clinically discarded biological samples from five patients
(5–7 years old) at the Department of Pediatric Dentistry
of Kyushu University Hospital under the approval of the
Kyushu University Institutional Review Board for Human
Genome/Gene Research (protocol number: 393–01). Written
informed consent was obtained from all parents on be-
half of the participants.
Mice
C57BL/6J-lpr/lpr mice (female, 8 weeks old), and preg-
nant and young adult C57BL/6J mice (female, 8 weeks
old) were purchased from Japan SLC (Shizuoka, Japan)
and CLEA Japan (Tokyo, Japan), respectively. All animal
experiments were approved by the Institutional Animal
Care and Use Committee of Kyushu University (protocol
number: A21-044-1).
Human MSC isolation and culture
Human MSCs were isolated based on the adherent
colony-forming unit fibroblasts (CFU-F) method [20].
Bone marrow cells (BMCs) (AllCells, Berkeley, CA,
USA) were seeded at 1×107 cells per T-75 culture flask
as described previously [21]. The dental pulp tissues of
human exfoliated deciduous teeth were minced and then
digested with 0.3 % collagenase type I (Worthington
Biochemicals, Lakewood, NJ, USA) and 0.4 % dispase II
(Sanko Junyaku, Tokyo, Japan) for 60 minutes at 37 °C
as reported previously [16]. Single cell suspensions were
obtained by passing the digested tissue through a 70-μm
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then seeded at 1×106 cells per T-75 culture flask. After 3 h,
non-adherent cells were removed by washing with
phosphate-buffered saline (PBS). Adherent cells were cul-
tured at 37 °C in 5 % CO2. The growth medium consisted
of α-minimum essential medium (αMEM; Invitrogen,
Carlsbad, CA, USA) supplemented with 15 % fetal bovine
serum (FBS; Equitech-Bio, Kerrville, TX, USA), 100 μM
L-ascorbic acid 2-phosphate (Wako Pure Chemical
Industrials, Osaka, Japan), 2 mM L-glutamine (Nacalai
Tesque, Kyoto, Japan), and mixed antibiotics containing
100 U/ml penicillin and 100 μg/ml streptomycin (Nacalai
Tesque). The growth medium was changed twice a week.
Adherent colony-forming cells were subcultured after
14–16 days.
To identify the isolated cells as MSCs, passage 3 (P3)
cells (1×105/100 μl) were stained with specific antibodies
against stem cell markers including CD11b, CD14, CD35,
CD45, CD73, CD90, CD105 and CD146 (1 μg/ml each;
eBioscience, San Diego, CA, USA) and then analyzed
using a flow cytometer (FACSVerse, BD Biosciences). The
percentages of positive cells were determined by compari-
son with the corresponding control cells stained with an
isotype-matched antibody, in which a false-positive rate of
less than 1 % was acceptable. The isolated cells were posi-
tive for CD73, CD90, CD105, and CD146, and negative
for CD11b, CD14, CD35, and CD45 (data not shown).
Furthermore, P3 cells were cultured under osteogenic,
chondrogenic, or adipogenic conditions [17, 18], and
showed differentiation capacities for osteoblasts (odonto-
blasts in the case of SHED), chondrocytes, and adipocytes
(data not shown). These findings showed that our isolated
cells were MSCs based on the standard MSC criteria [22].Systemic MSC transplantation into MRL/lpr mice
P3 hBMMSCs and SHED were collected and washed with
PBS three times. The donor cells were diluted in PBS, and
intravenously infused at 1×105 per 10 g body weight into
16-week-old MRL/lpr mice via the right cervical vein ac-
cording to a previously published method [16]. The mice
were analyzed at 20 weeks of age. Age-matched MRL/lpr
mice that received PBS were used as controls.Enzyme-linked immunosorbent assays of biological
(blood serum and bone marrow) and culture (culture
supernatant) samples
C-terminal telopeptides of type I collagen (CTX), interleu-
kin (IL)-17, and soluble receptor activator for nuclear factor
κB (NF-κB) ligand (sRANKL) in the samples were mea-
sured using enzyme-linked immunosorbent assay (ELISA)
kits (IL-17 and sRANKL, R&D Systems, Minneapolis, MN,
USA; CTX, Nordic Bioscience Diagnostics A/S, Herlev,
Denmark) according to the manufacturer’s instructions.Microcomputed tomographic bone analysis
Femoral bones of mice were analyzed by microcomputed
tomography (microCT) with a 1076 microCT system
(Skyscan, Kontich, Belgium), as previously described [23].
Density values were calibrated using hydroxyl apatite
phantoms with bone mineral density (BMD) values of
0.25 and 0.75 g/cm3 (Skyscan). BMD and bone structural
indices (bone volume/trabecular volume (BV/TV), tra-
becular thickness (Tb.Th), trabecular number (Tb.N), and
trabecular separation (Tb.Sp)) were calculated.
Histological bone analysis
Tibias were fixed with 4 % paraformaldehyde in PBS and
decalcified with 10 % ethylenediaminetetraacetic acid.
Paraffin sections were prepared at a thickness of 6 μm
and stained with tartrate-resistant acid phosphate
(TRAP) [21]. The number of TRAP-positive cells per
total bone area in the bone metaphysis was analyzed in
five representative images by Image J software (National
Institutes of Health, Bethesda, MA, USA).
Culture and stimulation of mouse BMCs
Mouse BMCs were cultured in Dulbecco’s modified
Eagle’s medium (Nacalai Tesque) supplemented with
10 % FBS, 50 μM 2-mercaptoethanol (Invitrogen), 10 mM
HEPES (Nacalai Tesque), 1 mM sodium pyruvate
(Nacalai Tesque), 1 % non-essential amino acid
(Nacalai Tesque), 2 mM L-glutamine, 100 U/ml peni-
cillin, and 100 μg/ml streptomycin with plate-bound
anti-CD3 (1 μg/ml; eBioscience) and soluble anti-
CD28 (1 μg/ml; eBioscience) antibodies on 24-well
plates. The conditioned medium (CM) was collected
and enriched ten-fold.
Th17 cell assay of cultured mouse BMCs
Cultured BMCs were flashed out from mouse long bones
(femurs and tibias), and treated with 0.82 % NH4Cl in PBS
for 15 minutes at room temperature. The BMCs (1×105 in
100 μl) were then incubated with PerCP-conjugated anti-
CD4 antibody (1 μg; eBioscience) and then R-PE-
conjugated anti-IL-17 (eBioscience) and APC-conjugated
anti-interferon (IFN) gamma (eBioscience) antibodies
(1 μg each). Isotype-matched antibodies (eBioscience)
were used as controls. The number of CD4+IL-17+IFNγ−
Th17 cells per 1×104 cells was measured on the flow
cytometer.
Isolation and culture of mouse BMMSCs
Mouse BMMSCs were isolated based on the CFU-F
method [23]. BMCs were seeded at 1–2×107 cells per
100-mm culture dish. After 3 h, the cells were washed
with PBS twice to eliminate non-adherent cells, and the
attached cells were cultured for 14–16 days. Attached col-
onies consisting of spindle-shaped cells were observed
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were passaged once. The cells were cultured in αMEM
supplemented with 20 % FBS, 2 mM L-glutamine, 55 μM
2-mercaptoethanol, 100 U/ml penicillin, and 100 μg/ml
streptomycin. Based on the MSC criteria [22], the colony-
forming cells were characterized as described previously
[24]: 1) flow cytometry demonstrated immunophenotypes
of CD73, CD105, CD146, Sca-1, and SSEA-4, and negativ-
ity for CD14, CD34, and CD45; 2) mouse BMMSCs were
evaluated for differentiation into osteoblasts, chondro-
cytes, and adipocytes under the corresponding specific
culture conditions.
In vitro osteogenic capacity of mouse BMMSCs
Mouse BMMSCs were cultured under osteogenic con-
ditions. The osteogenic medium consisted of αMEM
containing 20 % FBS, 2 mM L-glutamine, 55 μM 2-
mercaptoethanol, 100 μM L-ascorbic acid 2-phosphate (Wako
Pure Chemical Industrials), 2 mM β-glycerophosphate (Sigma,
St. Louis, MO, USA), 10 nM dexamethasone (Sigma),
100 U/ml penicillin, and 100 μg/ml streptomycin. The
cultures performed in the presence or absence of CM
of mouse BMCs and 10 nM recombinant mouse IL-17
(R&D Systems) with or without 1 μg/ml rat anti-mouse
IL-17 IgG2A antibody (R&D Systems) or the control
antibody, rat IgG2A antibody (R&D Systems), for 4
weeks. The ten-fold-enriched CM was mixed with the
osteogenic medium at a ratio of 1:9. The cultures were
stained with 1 % Alizarin Red solution [21]. Alizarin Red-
positive areas were quantified by Image J software [21].
In vitro osteoclast assay
We co-cultured mouse BMCs (1×106/well) with mouse
calvarial cells (1×105/well) or mouse BMMSCs (1×105/
well). Some mouse BMMSCs were pretreated with CM
of mouse BMCs or 10 nM recombinant mouse IL-17 in
the presence 1 μg/ml anti-mouse IL-17 antibody or the
control antibody for 3 days. Some mouse BMCs (1×106/
well) were pretreated with IL-17 and control siRNAs
(53 nM; Santa Cruz Biotechnology, Dallas, TX, USA)
according to the manufacturer’s instruction for 24 h at
37 °C and then continued to be cultured in the above
medium. The ten-fold-enriched CM was mixed with
the growth medium at a ratio of 1:9. Mouse calvarial
bones were harvested from 2–3-day-old wild-type
C57BL/6 mice and the calvarial cells were isolated with
a sequential enzymatic method [23]. The osteoclasto-
genic medium consisted of αMEM containing 10 %
FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 10 nM
vitamin D3 (Wako Pure Chemical Industrials), and 1 nM
prostaglandin E2 (Wako Pure Chemical Industrials) for
7 days. BMCs were also stimulated with 10 ng/ml
macrophage-colony stimulating factor (M-CSF; R&D
Systems) and 50 ng/ml RANKL (PeproTec, Rocky Hill,NJ, USA) for 5 days. The cultures were treated with
TRAP staining [23]. TRAP-positive multinucleated cells
(MNCs) (>3 nuclei) were determined as osteoclast-like
cells [23].
Western blotting
All the samples were lyzed in M-PER mammalian
protein extraction reagent (Thermo, Rockford, IL,
USA) containing proteinase inhibitor cocktail (Nacalai
Tesque). They were separated by sodium dodecyl sulfate-
polyacrylamide gel and transferred to Immobilon-P mem-
branes (Millipore, Billerica, MA, USA). The membranes
were blocked with 5 % skimmed milk in Tris-buffered sa-
line (150 mM NaCl and 20 mM Tris–HCl, pH 7.2) for 1 h
at room temperature and then incubated with anti-mouse
IL-17 antibody overnight at 4 °C. They were then treated
with horseradish peroxidase-conjugated donkey anti-
rabbit or anti-mouse IgG antibody (1:1000; Santa Cruz
Biotechnology) for 1 h at room temperature. The bound
antibodies were visualized using SuperSignal West Pico
(Thermo).
Statistical analysis
Data were analyzed by the one-way analysis of variance
F-test. P-values of less than 0.05 were considered to be
significant.
Supplementary materials and methods
Supplementary materials and methods are provided as
Additional file 1.
Results
Systemic human MSC transplantation ameliorates SLE
disorders in MRL/lpr mice
According to a previous method [16], hBMMSCs and
SHED (1×105 per 10 g body weight) were systemically
transplanted through the right cervical vein into MRL/
lpr mice at 16 weeks of age (Fig. S1a in Additional file 2),
following which they exhibited severe autoimmune disor-
ders including abnormal autoantibody increments and se-
vere renal nephritis (Fig. S1b and c in Additional file 2)
[10]. The systemic transplantation of human MSCs was
followed by evaluation of their immune therapeutic effi-
cacy in the SLE-like disorders, such as hyper-autoimmune
antibody production and renal dysfunction in MRL/lpr
mice at 4 weeks post-transplantation (Fig. S1b and c in
Additional file 2) as described previously [16, 17].
Systemic human MSC transplantation improves secondary
bone loss in MRL/lpr mice
Severe osteoporosis with progressive trabecular bone
breakdown occurs secondarily in SLE model MRL/lpr
mice at 16 weeks of age (Fig. 1) [10] and SLE patients



















































Fig. 1 (See legend on next page.)
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Fig. 1 Systemic human MSC transplantation ameliorates the bone loss in MRL/lpr mice. a–c Morphological analyses of mouse tibias. a Representative
micro-computed tomography (microCT) images of trabecular bone structures (yellow-dashed areas). Pre-Tx (16w) pre-transplant stage of MRL/lpr mice at 16
weeks of age; Post-Tx (20w) post-transplant stage of MRL/lpr mice at 20 weeks of age. b Bone mineral density (BMD). c Trabecular bone parameter assay. BV/
TV bone volume ratio to tissue volume; Tb.N trabecular number; Tb.Sp trabecular separation; Tb.Th trabecular thickness. d, e In vivo osteoclast activity assay.
d ELISA analyses of mouse serum. CTX C-terminal telopeptides of type I collagen; sRANKL soluble RANKL. e Histological analysis of recipient
tibias by TRAP staining. TRAP+ cells TRAP-positive osteoclast-like cells. hBMMSC-T human bone marrow mesenchymal stem cell-transplanted
MRL/lpr mice at 20 weeks; Pre-MRL/lpr pre-transplant MRL/lpr mice at 16 weeks of age; SHED-T stem cells from exfoliated deciduous teeth-transplanted
MRL/lpr mice at 20 weeks. n = 5 for all groups. *P < 0.05, **P < 0.01, ***P < 0.005. Values are shown as means ± SD
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examined the detailed in vivo skeletal metabolism in MRL/
lpr mice at 4 weeks after hBMMSCs and SHED transplant-
ation. MicroCT and histological analyses showed that sys-
temic transplantation of hBMMSCs and SHED recovered
the BMD and trabecular bone structures in MRL/lpr mice
(Fig. 1a–c, Fig. S2a in Additional file 2). Real-time reverse
transcription polymerase chain reaction (RT-PCR) demon-
strated that the long bones of human MSC-transplanted
MRL/lpr mice expressed higher levels of osteoblast-specific
genes (runt-related transcription factor 2 (Runx2), alkaline
phosphatase (Alp), and osteocalcin) than those in non-
transplanted MRL/lpr mice (Fig. S2b in Additional
file 2). Furthermore, compared with non-transplanted
mice, human MSC transplantation markedly reduced the
serum bone resorption markers sRANKL and CTX as
shown by ELISA (Fig. 1d) and the number of TRAP-
positive cells in the epiphysis of long bones as demon-
strated by histological analysis (Fig. 1e, Fig. S2c in
Additional file 2). These findings suggested that human
MSC transplantation recovered the bone reduction in
MRL/lpr mice via accelerated bone formation and sup-
pressed bone resorption, but did not elucidate the detailed
therapeutic mechanisms at cellular and molecular levels.Systemic human MSC transplantation recovers
dysregulation of osteoblast and osteoclast development
via recipient BMMSCs in MRL/lpr mice
Dysregulation of osteoblast and osteoclast development
in bone marrow leads to skeletal dysfunction. BMMSCs
play a crucial role in the development of osteoblasts and
osteoclasts in bone marrow [25–27]. Recent studies
showed that recipient BMMSCs in SLE mice and patients
impaired the stemness and osteogenic capacity [10, 19].
Therefore, we hypothesized that recipient BMMSCs might
participate in the osteoporosis of SLE and may be a thera-
peutic target. We isolated recipient BMMSCs from non-,
hBMMSC-, and SHED-transplanted MRL/lpr mice, and
designated them as MSC-MRL/lpr, MSC-hBMMSC, and
MSC-SHED, respectively. We also isolated recipient
BMMSCs from pre-transplant MRL/lpr mice at 16 weeks
of age (designated as MSC-Pre-MRL/lpr). MSC-hBMMSCand MSC-SHED showed lower CFU-F numbers, a higher
population-doubling score, and an elevated cell prolif-
eration rate compared with those of MSC-MRL/lpr, as
well as MSC-Pre-MRL/lpr (Fig. S3 in Additional file 2).
Next, we examined the osteogenic capacity of recipient
BMMSCs. Alizarin Red staining showed markedly lower
mineral deposition by MSC-Pre-MRL/lpr and MSC-MRL/
lpr than that by wild-type mouse-derived MSCs (MSC-WT)
at 4 weeks after osteogenic induction (data not shown).
Compared with MSC-Pre-MRL/lpr and MSC-MRL/lpr,
MSC-hBMMSC and MSC-SHED showed enhanced mineral
accumulation (Fig. 2a and b) and osteoblast-specific gene
expression (Fig. S4a in Additional file 2).
Furthermore, we examined the effects of human MSC
transplantation on recipient BMMSC-dependent osteo-
clastic differentiation. Recipient BMMSCs were co-
cultured with BMCs derived from wild-type mice
(BMC-WT) under stimulation with vitamin D3 and
prostaglandin E2. TRAP staining demonstrated that
MSC-MRL/lpr, as well as MSC-Pre-MRL/lpr, showed
enhanced TRAP-positive MNCs compared with that of
MSC-WT (data not shown). Moreover, compared with
MSC-Pre-MRL/lpr and MSC-MRL/lpr, this co-culture
assay showed that MSC-hBMMSC and MSC-SHED had
remarkably reduced capacities for differentiation into
TRAP-positive MNCs (Fig. 2c) and suppressed expres-
sion of osteoclast-specific genes (nuclear factor of
activated T-cells (Nfatc1), calcitonin receptor, and ca-
thepsin K) (Fig. S4b in Additional file 2). Taken together,
these data suggested that hBMMSC and SHED trans-
plantation improved the dysfunction of recipient
BMMSCs by induction of osteoblasts and suppression
of osteoclasts to regenerate abnormal skeletal structures
in MRL/lpr mice.
Systemic human MSC transplantation suppresses
abnormal IL-17 production in the bone marrow of
recipient MRL/lpr mice
The proinflammatory cytokine IL-17 is produced and se-
creted by a subset of helper T cells called Th17 cells,
and contributes to the autoimmune progression in SLE
[28, 29]. MRL/lpr mice express a significant increment



































































































Fig. 2 (See legend on next page.)
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Fig. 2 Systemic human MSC transplantation recovers bone metabolism and IL-17 production in bone marrow of MRL/lpr mice. a, b Osteogenic capacity
of recipient BMMSCs. Alizarin Red staining at 4 weeks after osteogenic induction. c, d Osteoclast inductivity of recipient BMMSCs in co-culture with
wild-type BL/6 mice-derived bone marrow cells (BMC-WT) under stimulation with 1α, 25-(OH)2 vitamin D3 and prostaglandin E2. TRAP staining. TRAP+ MNCs
tartrate-resistant acid phosphate-positive multinucleated cells. e, f Production of interleukin-17 (IL-17) in recipient bone marrow cells (BMCs). e A schema
of recipient BMC culture. BMCs were cultured under stimulation with anti-CD3 (Anti-CD3 Ab) and anti-CD28 (Anti-CD28 Ab) antibodies, and then IL-17 was
measured in the conditioned medium (CM IL-17). f ELISA of CM IL-17. BMC-hBMMSC bone marrow cells isolated from human bone marrow mesenchymal
stem cell-transplanted MRL/lpr mice at 20 weeks of age; BMC-MRL/lpr bone marrow cells isolated from non-transplanted MRL/lpr mice at 20 weeks of age;
BMC-Pre-MRL/lpr, bone marrow cells isolated from pre-transplant MRL/lpr mice at 16 weeks of age; BMC-SHED bone marrow cells isolated from stem cells
from exfoliated deciduous teeth-transplanted MRL/lpr mice at 20 weeks of age; MSC-hBMMSC bone marrow mesenchymal stem cells isolated from human
bone marrow mesenchymal stem cell-transplanted MRL/lpr mice at 20 weeks of age; MSC-MRL/lpr bone marrow mesenchymal stem cells isolated from
non-transplanted MRL/lpr mice at 20 weeks of age; MSC-Pre-MRL/lpr bone marrow mesenchymal stem cells isolated from pre-transplant MRL/lpr mice at 16
weeks of age; MSC-SHED bone marrow mesenchymal stem cells isolated from stem cells from exfoliated deciduous teeth-transplanted MRL/lpr mice at 20
weeks of age; Pre-Tx (16w) pre-transplant stage of MRL/lpr mice at 16 weeks of age; Post-Tx (20w) post-transplant stage of MRL/lpr mice at 20 weeks of age.
n = 5 for all groups. *P < 0.05, **P < 0.01, ***P < 0.005. Values are shown as means ± SD
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previously [10]. We examined the immunoregulatory ef-
fect of hBMMSCs and SHED on IL-17 production using
a co-culture system of human MSCs with human T cells
in the presence of transforming growth factor-β1 and IL-
6. This co-culture system demonstrated that hBMMSCs
and SHED suppressed both Th17 cell differentiation and
IL-17 secretion by flow cytometric analysis and ELISA,
respectively (Fig. S5a and b in Additional file 2). To con-
firm in vivo immunological effects of hBMMSCs and
SHED on IL-17 secretion, we analyzed peripheral levels
of Th17 cells and IL-17 in MRL/lpr mice. Immuno-
logical analyses showed that hBMMSCs and SHED sup-
pressed systemic Th17 cells and IL-17 expression in
MRL/lpr mice, as well as pre-transplant MRL/lpr mice
(Fig. S5c and d in Additional file 2). These findings indi-
cated that hBMMSCs and SHED expressed a suppressive
regulation of Th17 cell differentiation in vitro and
in vivo, as reported previously [10, 16].
Carboxyfluorescein diacetate succinimidyl ester (CFSE)-
labeled hBMMSCs and SHED were infused intravenously
into MRL/lpr mice. Subsequently, these cells were found
in the recipient bone marrow space at days 1 and 7 after
infusion, but the positive cell number was lower at day 7
than that at day 1 (Fig. S6a in Additional file 2). IL-17 is
significantly increased in the bone marrow of MRL/lpr
mice [10]. We analyzed IL-17 levels in bone marrow tis-
sues of hBMMSC- and SHED-transplanted MRL/lpr mice
in comparison with non-transplanted MRL/lpr mice. In
immunofluorescence analysis, hBMMSC and SHED trans-
plantation resulted in a marked decrease in IL-17-positive
cells in the recipient bone marrow (Fig. S6b in Additional
file 2). Flow cytometric analysis and ELISA showed reduc-
tions of CD4+IL-17+IFNγ− Th17 cells and IL-17 in the
recipient bone marrow tissues of hBMMSC- and SHED-
transplanted groups, respectively, when compared to pre-
transplant and non-transplanted MRL/lpr mice (Fig. S6c
and d in Additional file 2). To assess the productivity ofIL-17 in recipient bone marrow, we individually
cultured the four types of recipient BMCs (BMC-Pre-
MRL/lpr, BMC-MRL/lpr, BMC-hBMMSC, and BMC-
SHED) from pre-transplant, and non-, hBMMSC- and
SHED-transplanted MRL/lpr mice, respectively, under
T cell activation conditions stimulated with anti-CD3
and anti-CD28 antibodies for 3 days and then measured
IL-17 in the CMs by ELISA (Fig. 2e). BMC-hBMMSC
and BMC-SHED exhibited lower production of IL-17
than BMC-MRL/lpr, as well as BMC-Pre-MRL/lpr
(Fig. 2f ), reflecting the recipient bone marrow IL-17
conditions. Taken together, these findings indicated that
transplanted hBMMSCs and SHED might suppress the
abnormal IL-17 production in the recipient bone mar-
row of MRL/lpr mice, but did not evaluate whether the
recipient IL-17 conditions effected on the dysregulation
by osteoclastic bone resorption and osteoblastic bone
formation in MRL/lpr mice.
To understand the mechanistic transplant studies, we
transplanted hBMMSCs and SHED (1×105 per 10 g body
weight) into wild-type C57BL/6 mice at 16 weeks of age,
and analyzed the effects of the transplants 4 weeks after
the infusion (Fig. S1a in Additional file 2). There was no
effect of hMSC transplantation on bone metabolism and
IL-17 levels (Fig. S7 in Additional file 2). These findings
suggested that recipient inflammatory conditions might
influence the transplants’ ability to treat recipient bone
metabolism.
Systemic human MSC transplantation rescues impaired
osteogenic capacity of recipient BMMSCs through
IL-17-dependent immune conditions in the recipient
bone marrow of MRL/lpr mice
In preliminary examinations, MSC-WT were cultured
under osteogenic conditions in the presence of IL-17
and CM of BMC-MRL/lpr (CM-MRL/lpr) (Fig. S8a and b
in Additional file 2). The treatments of IL-17 and CM-
MRL/lpr led to a significant reduction in the osteogenic
Ma et al. Stem Cell Research & Therapy  (2015) 6:104 Page 9 of 17capacity of MSC-WT as demonstrated by Alizarin Red
staining (Fig. S8a and b in Additional file 2). Anti-IL-17
antibody treatment reversed the suppressed osteogenic
capacity in IL-17- and CM-MRL/lpr-treated MSC-WT
when co-treated with the control antibody treatment
(Fig. S8a and b in Additional file 2). These preliminary
data suggested that IL-17 conditions in the recipient
bone marrow might modulate the osteoblastic differen-
tiation of recipient BMMSCs in MRL/lpr mice. We
then examined whether IL-17-dependent immune con-
ditions in recipient bone marrow affected recipient
BMMSC-mediated bone formation. Mouse BMMSCs
were cultured under osteogenic conditions with or with-
out CM collected from BMC-hBMMSC and BMC-SHED
cultures (CM-hBMMSC, and CM-SHED, respectively), as
well as CM-MRL/lpr, in the presence or absence of anti-
mouse IL-17 antibody (Fig. 3a). The control antibody for
anti-mouse IL-17 antibody was used as the control treat-
ment. Alizarin Red staining results showed that CM-
MRL/lpr significantly suppressed the osteogenic capacity
of MSC-WT (Fig. 3b, Fig. S8b in Additional file 2),
whereas CM-hBMMSC and CM-SHED showed little sup-
pressive effects on the osteogenic capability of MSC-WT
(Fig. 3b). Anti-IL-17 antibody treatment neutralized the
inhibited osteogenic capability by the individual CMs,
especially in the CM-MRL/lpr-treated group (Fig. 3b,
Fig. S8b in Additional file 2). These results suggested that
the hyperactivity of IL-17 in recipient bone marrow of
MRL/lpr mice might cause the severe defective bone for-
mation mediated by recipient BMMSCs.
Next, we investigated the effect of abnormal IL-17 in
recipient bone marrow of MRL/lpr mice on recipient
BMMSC-mediated bone formation. Recipient BMMSCs,
including MSC-MRL/lpr, MSC-hBMMSC and MSC-
SHED, were treated with CM-MRL/lpr under osteogenic
conditions. CM-MRL/lpr treatment significantly suppressed
the mineralized deposition induced by MSC-hBMMSC and
MSC-SHED (Fig. 3c). The suppressed MSC-hBMMSC-
and MSC-SHED-induced mineralization showed similar
rates to MSC- MRL/lpr-induced bone formation (Fig. 3c).
The CM-MRL/lpr treated suppression was recovered by
the treatment with anti-IL-17 antibody (Fig. 3c). We then
cultured individual recipient BMMSCs under osteogenic
conditions in the presence of IL-17. IL-17 significantly
suppressed the mineralized deposition induced by MSC-
hBMMSC and MSC-SHED, which showed similar depos-
ition rates to that of MSC-MRL/lpr (Fig. 3d). Anti-IL-17
antibody treatment completely neutralized the IL-17-
suppressed osteogenic capacities of MSC-hBMMSC and
MSC-SHED (Fig. 3d). These findings indicated that abnor-
mal IL-17 in the bone marrow of MRL/lpr mice impaired
the osteogenic capacity of recipient BMMSCs, and sug-
gested that hBMMSC and SHED transplantation recov-
ered the osteogenic dysfunction of recipient BMMSCsthrough inhibiting hyperactivated IL-17 in the recipient
bone marrow of MRL/lpr.
Systemic human MSC transplantation rescues impaired
recipient BMMSC-mediated osteoclast induction through
IL-17-dependent immune conditions in the recipient bone
marrow of MRL/lpr mice
We also preliminarily examined the effects of IL-17 and
CM-MRL/lpr on osteoclast differentiation in the co-
culture system with BMC-WT and wild-type mouse-
derived calvarial cells (Calvaria-WT). BMC-WT were
co-cultured with Calvaria-WT under the stimulation of
vitamin D3 and prostaglandin E2 in the presence or ab-
sence of IL-17 and CM-MRL/lpr (Fig. 4a). The control
antibody for anti-mouse IL-17 antibody was also used as
the control treatment. TRAP staining showed that both
IL-17 and CM-MRL/lpr treatments induced TRAP-
positive MNCs in the co-culture system (Fig. S8c and d
in Additional file 2). The enhanced TRAP-positive
MNC-induction was reversed when treated with anti-IL-
17 antibody in the presence of IL-17 and CM-MRL/lpr
(Fig. S8c and d in Additional file 2). In the co-culture
system of BMC-WT and Calvaria-WT, CM-hBMMSC
and CM-SHED treatments showed a fewer number of
TRAP-positive MNCs than CM-MRL/lpr treatment
(Fig. 4b). Anti-IL-17 antibody treatment reduced the
number of TRAP-positive MNCs under the stimulation
of CM-hBMMSC and CM-SHED (Fig. 4b). Subsequently,
we co-cultured Calvaria-WT with recipient BMCs. In-
duction of TRAP-positive MNCs in the co-culture sys-
tems with BMC-hBMMSC and BMC-SHED showed a
fewer number of TRAP-positive MNCs than that with
BMC-MRL/lpr (Fig. 4c and d). Treatment with CM-
MRL/lpr and IL-17 stimulated the reduced osteoclast in-
duction in the co-culture systems with BMC-hBMMSC
and BMC-SHED (Fig. 4c and d). Anti-IL-17 antibody
treatment neutralized the CM-MRL/lpr- and IL-17-
enhanced TRAP-positive MNC-induction in the co-
culture systems with BMC-hBMMSC and BMC-SHED
(Fig. 4c and d). These results suggested that IL-17-
dependent immune conditions in the recipient bone
marrow might modulate osteoclastic differentiation and
bone resorption in MRL/lpr mice.
To examine whether IL-17-dependent immune condi-
tions in recipient bone marrow affect recipient BMMSC-
mediated osteoclast induction, we pretreated recipient
BMMSCs with CM of recipient BMC culture or IL-17 in
the presence or absence of anti-IL-17 antibody. In the
co-culture system of MSC-MRL/lpr and BMC-MRL/lpr,
TRAP staining demonstrated that CM-MRL/lpr-en-
hanced TRAP-positive MNC induction was reduced
when pretreated with CM-hBMMSC and CM-SHED
(Fig. 4e). BMC-MRL/lpr were then co-cultured with












































































































































































Fig. 3 Systemic human MSC transplantation recovers IL-17-impaired recipient BMMSC-mediated osteogenesis in the bone marrow of MRL/lpr
mice. a A schema of the osteogenic capacity of recipient bone marrow mesenchymal stem cells (BMMSCs). Recipient BMMSCs were induced by
ascorbic acid (AA) and inorganic phosphate (Pi), and treated with or without recipient BMC-derived conditioned medium (CM) in the presence of
anti-mouse IL-17 antibody (Anti-IL-17 Ab), control antibody for anti-mouse IL-17 antibody (Cont Ab) or recombinant mouse IL-17 (IL-17). b–d
Osteogenic assay by Alizarin Red staining at 4 weeks after osteogenic induction. n=5 for all groups. Values are shown as means ± SD. **P < 0.01,
***P < 0.005. #P < 0.05, ##P < 0.01, ###P < 0.005, versus MSC-WT treated with CM-MRL/lpr in the presence of Cont Ab. †††P < 0.005, versus MSC-MRL/
lpr. CM-hBMMSC conditioned medium of BMC-hBMMSC culture under stimulation with anti-CD3 and CD28 antibodies; CM-MRL/lpr, conditioned
medium of BMC-MRL/lpr culture under stimulation with anti-CD3 and CD28 antibodies; CM-SHED conditioned medium of BMC-SHED culture under
stimulation with anti-CD3 and CD28 antibodies; MSC-WT BMMSCs isolated from wild-type C57BL/6 mice
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tions in comparison with MSC-MRL/lpr (Fig. 4f and g).
CM-MRL/lpr-pretreated recipient BMMSCs significantly
enhanced the TRAP-positive MNC induction from
BMC-MRL/lpr in the respective co-culture system, but
the pretreatment effects on MSC-hBMMSC and MSC-
SHED were less than those on MSC-MRL/lpr (Fig. 4f ).
Anti-IL-17 antibody co-pretreatment blocked the CM-
MRL/lpr-enhanced TRAP-positive MNCs in the individ-
ual co-culture system (Fig. 4f ). We then examined
whether IL-17 treatment in recipient BMMSCs directlyaffected the osteoclast inductivity in the co-culture system
with BMC-MRL/lpr. IL-17-pretreated MSC-hBMMSC
and MSC-SHED, as well as MSC-MRL/lpr, significantly
induced TRAP-positive MNCs, but the inductivity by IL-
17-pretreated MSC-hBMMSC and MSC-SHED was less
than that by IL-17-pretreated MSC-MRL/lpr (Fig. 4g).
The increased TRAP-positive MNC inductivity was
inhibited when the recipient BMMSCs were co-
pretreated with anti-IL-17 antibody (Fig. 4g). These
findings suggested that IL-17-dependent hyperimmune






































































































































































































































































































































































































Fig. 4 (See legend on next page.)
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Fig. 4 Systemic human MSC transplantation recovers IL-17-accelerated recipient BMMSC-mediated osteoclastogenesis in the bone marrow of
MRL/lpr mice. a A schema of osteoclastic induction. Mouse bone marrow cells (BMCs) were co-cultured with wild-type mouse-derived calvarial
cells (Calvaria-WT) or recipient bone marrow mesenchymal stem cells (BMMSCs) under stimulation with 1α, 25-(OH)2 vitamin D3 (VD3) and
prostaglandin E2 (PGE2). Calvaria-WT and recipient BMMSCs were pretreated with or without recipient BMC-derived conditioned medium (CM) or
interleukin-17 (IL17) in the presence of anti-mouse IL-17 antibody (Anti-IL-17 Ab) or control antibody for anti-mouse IL-17 antibody (Cont Ab). b–g
Osteoclast induction assay by tartrate-resistant acid phosphate (TRAP) staining. n = 5 for all groups. Values are shown as means ± SD. *P < 0.05,
**P < 0.01, ***P < 0.005. b Co-culture of Calvaria-WT and wild-type mice-derived bone marrow cells (BMC-WT). #P < 0.05, versus CM-MRL/lpr
pretreatment in the presence of Cont Ab; ††P < 0.01, versus CM-MRL/lpr pretreatment in the presence of Anti-IL-17 Ab. c, d Co-culture of
Calvaria-WT and recipient BMCs. ¶P < 0.05, ¶¶P < 0.01, ¶¶¶P < 0.005, versus BMC-MRL/lpr and Calvaria-WT co-culture. e Co-culture of BMC-MRL/lpr
and MSC-MRL/lpr. f, g Co-culture of BMC-MRL/lpr and recipient BMMSCs. ##P < 0.01, ###P < 0.005, versus co-culture of BMC-MRL/lpr and Cont
Ab-pretreated MSC-MRL/lpr . f ††P < 0.01, †††P < 0.005 versus co-culture of BMC-MRL/lpr and CM-MRL/lpr-pretreated MSC-MRL/lpr. g ¶P<0.05,
versus co-culture of BMC-MRL/lpr and IL-17- and Cont Ab-pretreated MSC-MRL/lpr co-culture pretreated with IL-17; ΔP < 0.05, ΔΔP < 0.01, versus
co-culture of BMC-MRL/lpr and IL-17- and Anti-IL-17 Ab-pretreated MSC-MRL/lpr. MNC multinucleated cell; MSC mesenchymal stem cell; SHED
stem cells from exfoliated deciduous teeth
Ma et al. Stem Cell Research & Therapy  (2015) 6:104 Page 12 of 17mice might impair recipient BMMSCs to accelerate ab-
normal osteoclast induction while human MSC trans-
plantation might target the impaired recipient BMMSCs
to suppress the enhanced osteoclast inductivity.
Functional downregulation of IL-17 in BMCs of MRL/lpr
mice inhibits recipient BMMSC-mediated osteoclast
differentiation
We examined whether IL-17 levels in recipient BMCs of
MRL/lpr mice play a significant role in osteoclast differen-
tiation through recipient BMMSCs. BMC-MRL/lpr were
treated with mouse IL-17 siRNA or the control siRNA,
and were co-cultured with recipient BMMSCs under
stimulation with 1α, 25-(OH)2 vitamin D3 and prostaglan-
din E2 (Fig. 5a). Some co-cultures were incubated in the
presence of anti-mouse IL-17 antibody or the control anti-
body (Fig. 5a). Western blotting confirmed that siRNA for
mouse IL-17 significantly downregulated the expression of
IL-17 in BMC-MRL/lpr (Fig. 5b). IL-17 siRNA-treated
BMC-MRL/lpr inhibited individual recipient BMMSC-
mediated osteoclast induction in the co-culture system,
but control siRNA-treated BMC-MRL/lpr did not (Fig. 5c).
IL-17 antibody treatment also suppressed osteoclast differ-
entiation in a co-culture system of intact BMC-MRL/lpr
and individual recipient BMMSCs (Fig. 5d). Furthermore,
to understand whether IL-17 levels in recipient BMCs
affect direct capabilities of osteoclast differentiation of the
BMCs, recipient BMCs were cultured in a RANKL-M-
CSF culture system (Fig. 5e). Although IL-17 siRNA treat-
ment in individual BMCs efficiently induced TRAP-
positive MNCs, the efficiency was similar to the control
cultures treated with control siRNA (Fig. 5f). Anti-IL-17
antibody treatment showed no effect on TRAP-positive
MNC formation from individual recipient BMCs in a
RANKL-M-CSF culture system when compared to the
control antibody treatment (Fig. 5g). In addition, osteo-
clast formation in a RANKL-M-CSF system expressed a
similar efficacy among individual recipient BMCs (Fig. 5fand g). These finding suggested that IL-17 levels in recipi-
ent BMCs might affect recipient BMMSC-mediated osteo-
clast differentiation of recipient BMCs, but not direct
osteoclastogenesis of recipient BMCs.
Systemic treatment of anti-IL-17 antibody improves
secondary bone loss in MRL/lpr mice
To investigate a role of IL-17 on skeletal metabolism in
MRL/lpr mice, we systemically infused anti-IL-17 anti-
body to MRL/lpr mice at 16 weeks of age for 4 weeks
(Fig. S9a in Additional file 2). MicroCT analyses showed
that systemic treatment of anti-IL-17 antibody recovered
the BMD and trabecular bone structures when com-
pared to non-infused and isotype-matched IgG2a-
infused MRL/lpr mice (Fig. S9b-d in Additional file 2).
Real-time RT-PCR demonstrated that the long bones of
anti-IL-17 antibody-treated MRL/lpr mice expressed
higher levels of osteoblast-specific genes (Runx2, Alp,
and osteocalcin) than those in non-infused and isotype-
matched IgG2a-infused MRL/lpr mice (Fig. S10a in Add-
itional file 2). Moreover, compared with non-infused and
isotype-matched IgG2a-infused MRL/lpr mice, anti-IL-
17 antibody treatment suppressed expression of
osteoclast-specific genes (Nfatc1, calcitonin receptor, and
cathepsin K) by real-time RT-PCR assay (Fig. S10b in
Additional file 2). ELISA also demonstrated that anti-IL-
17 antibody treatment markedly reduced serum bone re-
sorption markers including sRANKL and CTX in com-
parison with non-infused and isotype-matched IgG2a-
infused MRL/lpr mice (Fig. S10c in Additional file 2).
These findings suggested that systemic anti-IL-17 anti-
body treatment might recover the osteoporotic disorder
in MRL/lpr mice via accelerated bone formation and
suppressed bone resorption.
Discussion
The incidence of secondary osteoporosis in SLE patients










































































































































































































Fig. 5 (See legend on next page.)
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Fig. 5 Functional downregulation of IL-17 in bone marrow cells of MRL/lpr mice suppressed recipient BMMSC-mediated osteoclastogenesis. a–d
Osteoclast induction assay in bone marrow cell MRL/lpr (BMC-MRL/lpr) and recipient bone marrow mesenchymal stem cell (BMMSC) co-culture.
a A schema of osteoclast induction in a co-culture system. BMC-MRL/lpr were pretreated with or without mouse interleukin-17 siRNA (IL-17 siRNA)
and the control siRNA (Cont siRNA). Some BMCs were co-cultured with recipient BMMSCs under the stimulation with 1α, 25-(OH)2 vitamin D3
(VD3) and prostaglandin E2 (PGE2) in the presence of anti-mouse IL-17 antibody (Anti-IL-17 Ab) or control antibody for anti-mouse IL-17 antibody
(Cont Ab). b Expression of IL-17 in BMC-MRL/lpr pretreated with IL-17 siRNA and Cont siRNA by Western blotting. c, d Osteoclast induction assay
by tartrate-resistant acid phosphate (TRAP) staining. c Effects of IL-17 siRNA. d Effects of Anti-IL-17 Ab. e–g Direct osteoclast induction assay of
recipient BMCs. e A schema of a direct osteoclast induction in a receptor activator for nuclear factor κB ligand and macrophage-colony stimulating
factor (RANKL + M-CSF) system. Recipient BMCs were pretreated with or without IL-17 siRNA and Cont siRNA and cultured under a stimulation of
M-CSF and RANKL. Some BMCs were cultured in the presence of Anti-IL-17 Ab or Cont Ab. f, g Osteoclast induction assay by TRAP staining. f Effects of
IL-17 siRNA. g Effects of Anti-IL-17 Ab. n = 5 for all groups. Values are shown as means ± SD. *P < 0.05. c ¶P < 0.05, ¶¶¶P < 0.005, versus co-culture of
Cont siRNA-treated BMC-MRL/lpr and MSC-MRL/lpr. #P < 0.05, versus co-culture of IL-17 siRNA-treated BMC-MRL/lpr and MSC-MRL/lpr co-culture.
d ¶P < 0.05, ¶¶P < 0.01, ¶¶¶P < 0.005, versus co-culture of BMC-MRL/lpr and MSC-WT in the presence of Cont Ab. #P < 0.05, versus co-culture of
BMC-MRL/lpr and MSC-MRL/lpr in the presence of Anti-IL-17 Ab. MNC multinucleated cell; MSC mesenchymal stem cell; SHED stem cells from
exfoliated deciduous teeth
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which is related to menopause and aging, whereas
secondary osteoporosis in SLE is multifactorial and in-
volves excessive systemic inflammation and long-term
anti-inflammatory/immunosuppressive medications such
as glucocorticoids [25]. These risk factors lead to fragility
fractures, which are mainly vertebral fractures, and can
proceed to new fractures, increase the mortality rate, and
reduce quality of life [32, 33]. Among the numerous anti-
osteoporosis drugs to prevent and treat bone loss in SLE
patients, bisphosphonates are a first-line, anti-resorptive
agent but show little effect on bone reconstruction and
exhibit side effects such as negative fetus development,
osteonecrosis of the jaw, and musculoskeletal pain. Other
anti-osteoporotic agents, such as estrogen, calcitonin, and
raloxifene, exhibit various limitations in terms of potency,
population effects, and side effects [34]. From the view-
point of a quality of life-based medicine, novel therapeutics
have been strongly desired to recover the bone loss in SLE
patients. In this study, according to recent findings of
human MSC-based therapy [14–18], we systemically trans-
planted hBMMSCs and SHED into SLE model MRL/lpr
mice with a severe osteoporotic phenotype and assessed
their therapeutic effects on bone loss. Our results demon-
strated that human MSC-based therapy ameliorated bone
reduction in MRL/lpr mice.
Upon dysregulation of the bone remodeling balance by
osteoblasts and osteoclasts, the skeletal system enters a
pathological condition. In bone marrow, BMMSCs not
only serve as a source of osteoblasts, but also support
osteoclast differentiation [25–27]. Increasing evidence
has shown impaired functions in BMMSCs derived from
SLE patients [10, 19, 35, 36] and SLE model mice [10],
suggesting that a recipient BMMSC deficiency might
participate in the pathology of secondary osteoporosis in
SLE. However, recent studies demonstrate that systemic
MSC transplantation into MRL/lpr mice improves the
bone loss, although no study has focused on recipientBMMSCs in the bone regeneration process by systemic
transplantation of MSCs [10, 16, 17]. Therefore, we hy-
pothesized that the therapeutic effects of systemically
transplanted MSCs on bone regeneration in SLE were
mediated by recovery of deficient host BMMSCs. Inter-
estingly, in the present study, the exogenous hBMMSCs
and SHED recovered the impaired bone-forming cap-
ability of recipient BMMSCs and reduced abnormal
osteoclast induction via recipient BMMSCs in the bone
marrow of MRL/lpr mice. These findings suggest that
recovery of the impaired recipient BMMSCs might be a
critical process to regenerate the skeletal loss in MRL/
lpr mice after human MSC transplantation. However,
further studies should explore the cellular and molecular
mechanisms through which exogenous MSCs improve
the deficiency of recipient BMMSCs.
Inflammation shifts skeletal homeostasis to a bone re-
sorptive condition. Secondary osteoporosis in SLE involves
complex interplay of hyperactivated immune reactions and
abnormal bone metabolism. The proinflammatory cytokine
IL-17, which is produced by Th17 cells [37], has been in-
vestigated as a participant in various autoimmune diseases
[38, 39]. These findings suggest a novel role for IL-17 in
bone diseases such as rheumatoid arthritis and osteoporosis
[40, 41]. In this study, we demonstrated that IL-17-
dependent hyperimmune conditions in the recipient bone
marrow in MRL/lpr mice impaired recipient BMMSCs to
suppress the osteogenic function and accelerate the osteo-
clast induction. Our IL-17 neutralization experiments also
provided strong evidence that abnormal IL-17 expression
in the bone marrow of MRL/lpr mice impaired recipient
BMMSC-mediated osteogenesis and recipient BMMSC-
mediated osteoclast induction. However, our siRNA and
neutralizing antibody of IL-17 experiments also demon-
strated that IL-17 levels in recipient BMCs might affect
recipient BMMSC-mediated osteoclast differentiation of re-
cipient BMCs, but not influence osteoclastogenesis of
recipient BMCs directly. In bone metabolism, IL-17
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genesis-supporting cells, such as mesenchymal cells and
osteoblasts, but not in direct osteoclast induction stim-
ulated by M-CSF and RANKL [42, 43]. IL-17 also dir-
ectly inhibits osteoblastic differentiation of MSCs [44].
Therefore, these findings suggest that hyperactivated
IL-17 in recipient bone marrow may be responsible for
secondary osteoporosis in MRL/lpr mice by impairing
recipient BMMSCs. Furthermore, the present systemic
transplantation of hBMMSCs and SHED suppressed the
increased expression of bone marrow IL-17 in MRL/lpr
mice, and restored the impaired functions of recipient
BMMSCs in bone metabolism. NF-κB activation by pro-
inflammatory cytokines including IL-17 is known to
reduce the bone formation capacity of host BMMSCs
[19, 44]. Further efforts will be required to elucidate the
crucial mechanism of IL-17 in the recipient BMMSC-
based pathology of secondary osteoporosis in SLE,
which may lead to novel recipient BMMSC-targeting
therapeutics for skeletal disorders.
IL-17 antibody treatments have emerged as a novel
therapeutic approach for immune-mediated diseases such
as psoriasis, rheumatoid arthritis, psoriatic arthritis and
ankylosing spondylitis [45, 46]. Experimental evidence
demonstrated anti-IL-17 therapy could protect bone de-
struction in rheumatoid arthritis by reducing the number
of osteoclasts in joints as well as Th17 cells [47]. Anti-IL-
17 antibody also preserves skeletal loss in osteoporosis by
enhancing osteoblastic bone formation and suppressing
osteoclastic bone resorption, as well as protecting against
IL-17-mediated immune damages [48]. Several direct IL-
17 inhibitors (for example, secukinumab and ixekizumab,
anti-IL-17A monoclonal antibody) have shown exciting
advances in proof-of-concept and phase II clinical trials,
but also expected are further evaluations from phase III
clinical trials in multiple autoimmune and immune-
related inflammatory diseases [49]. In this study, we dem-
onstrated that systemic treatment of anti-IL-17 antibody
recovered bone reduction in MRL/lpr mice. The usage of
IL-17 antibody in treating secondary osteoporosis will not
only provide a therapeutic method but also improve the
understanding of disease pathogenesis.
In this study, we found that pathological immune con-
ditions affected recipient MSCs, and indicated that
hBMMSCs and SHED transplantation improved the
bone reduction by restoring IL-17-impaired recipient
BMMSCs after migration into the damaged bone
marrow. These results suggest that abnormal recipient
BMMSCs may undergo correction of their primary
functions by the post-transplantation actions of human
MSCs. Although the therapeutic mechanism of engrafted
human MSCs in the target bone site is not fully under-
stood, several possibilities may be involved in the post-
transplantation behaviors of human MSCs in impairedbone marrow. Migrated human MSCs have the potential
to participate directly in bone regeneration by differentiat-
ing into osteoblasts and suppressing osteoclast induction
[25–27]. However, bone reconstruction is affected by pro-
inflammatory cytokines at bone defect sites [50]. In
addition, MSCs act as cellular modulators through immu-
nomodulatory and trophic effects [51]. Immunomodula-
tory functions are inducted by cell-cell contact and
include FasL-mediated T cell apoptosis [52], CCR6-
mediated Th17 cell inhibition [53], and MSC-secreted
molecule (e.g., IL-10)-mediated Th17 cell suppression
[54]. Trophic molecules released from MSCs can inhibit
apoptosis and scar formation, such as macrophage
inflammatory protein-1, stromal cell-derived factor-1,
transforming growth factor-β1, and vascular endothelial
growth factor [55]. Therefore, exogenous MSCs may
exert their immunomodulatory and trophic functions by
secreting bioactive molecules to recover impaired re-
cipient BMMSCs. Further studies will be necessary to
explore the deeper mechanisms of transplanted MSC-
mediated recovery of recipient BMMSCs.
Conclusions
The present study demonstrates that systemic transplant-
ation of human MSCs, including SHED and hBMMSCs,
ameliorates severe bone reduction, as well as primary SLE
disorders, in MRL/lpr mice. The therapeutic efficacy is
mediated by recovery of the impaired functions of recipi-
ent BMMSCs to regulate osteogenesis and osteoclastogen-
esis via IL-17 suppression in the recipient bone marrow.
These data indicate that IL-17, as a cause of secondary
osteoporosis in SLE, might be a therapeutic target of
transplanted human MSCs in the skeletal disorder. Fur-
ther studies will be necessary to explore new cellular and
molecular strategies to overcome the recipient BMMSC-
based pathology of secondary osteoporosis in SLE and de-
velop a novel recipient BMMSC-targeting approach in
MSC-based therapy for skeletal regeneration.
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Additional file 2: Supplementary Figs. 1-10.
Abbreviations
ALP: alkaline phosphatase; αMEM: alpha minimum essential medium;
BMC: bone marrow cell; BMC-WT: wild-type mice-derived bone marrow
cells; BMD: bone mineral density; BMMSC: bone marrow mesenchymal
stem cell; BV/TV: bone volume/trabecular volume; Calvaria-WT: wild-type
mouse-derived calvarial cells; CFSE: carboxyfluorescein diacetate succinimidyl
ester; CFU-F: colony-forming unit fibroblasts; CM: conditioned medium;
CTX: C-terminal telopeptides of type I collagen; ELISA: enzyme-linked
immunosorbent assay; FBS: fetal bovine serum; hBMMSC: human bone
marrow mesenchymal stem cell; hUCMSC: human umbilical cord-derived
mesenchymal stem cell; IFN: interferon; IL: interleukin; M-CSF: macrophage-
colony stimulating factor; microCT: micro-computed tomography;
MNC: multinucleated cell; MSC: mesenchymal stem cell; MSC-WT: wild-type
Ma et al. Stem Cell Research & Therapy  (2015) 6:104 Page 16 of 17mice-derived mesenchymal stem cells; NFATc1: nuclear factor of activated
T-cells; NF-κB: nuclear factor κB; PBS: phosphate-buffered saline; RT-PCR: reverse
transcription polymerase chain reaction; Runx2: runt-related transcription factor
2; SHED: stem cells from exfoliated deciduous teeth; SLE: systemic lupus
erythematosus; sRANKL: soluble receptor activator for nuclear factor κB ligand;
Tb.N: trabecular number; Tb.Sp: trabecular separation; Tb.Spac: trabecular
space; Tb.Th: trabecular thickness; Th17: IL-17 producing helper T; TRAP:
tartrate-resistant acid phosphate.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LM: collection and assembly of data, data analysis and interpretation; RA, YH,
HY, ET, YT, SSo, GS, WZ, KN: data analysis and interpretation; SSh: conception
and design, data analysis and interpretation; TY: collection and assembly of
data, data analysis and interpretation, conception and design, data analysis
and interpretation, manuscript writing. All authors read and approved the
manuscript.
Acknowledgements
We are very thankful to Dr. Yusuke Makino, Kyushu University Hospital, for his
technical support. This work was supported by grants-in-aid for Scientific
Research (B) (No. 25293405 to TY) and (C) (No. 25463187 to HY) and the
Challenging Exploratory Research Project (No. 24659815 to TY and No.
25670877 to KN) of the Japan Society for Promotion of Science.
Author details
1Department of Molecular Cell Biology and Oral Anatomy, Kyushu University
Graduate School of Dental Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka
812-8582, Japan. 2Department of Pediatric Dentistry, Kyushu University
Graduate School of Dental Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka
812-8582, Japan. 3Department of Pediatric Dentistry, Guanghua School of
Stomatology, Hospital of Stomatology, Sun Yat-sen University, No. 56,
Lingyuan Xi Road, Guangzhou 510055, China. 4Department of Pediatric
Dentistry, School of Stomatology, Wuhan University, Luo-jia-shan, Wuchang,
Wuhan 430072, China. 5Guangdong Provincial Key Laboratory of
Stomatology, Sun Yat-sen University, No. 135, Xingang Xi Road, Guangzhou
510275, China. 6Center for Craniofacial Molecular Biology, Herman Ostrow
School of Dentistry of USC, University of Southern California, 2250 Alcazar
Street, Los Angeles, CA 90033-9062, USA. 7Department of Anatomy and Cell
Biology, School of Dental Medicine, University of Pennsylvania, 240 South
40th Street, Philadelphia, PA 19204-6030, USA.
Received: 22 September 2014 Revised: 16 February 2015
Accepted: 7 May 2015
References
1. Cooper C. Epidemiology of osteonecrosis. In: Favus M, editor. Primer on the
Metabolic Bone Disease and Disorders of Mineral Metabolism. Washington
DC: American Society for Bone and Mineral Research; 2003. p. 307–13.
2. Walker-Bone K. Recognizing and treating secondary osteoporosis. Nat Rev
Rheumatol. 2012;8:480–92.
3. Lane NE. Therapy Insight: osteoporosis and osteonecrosis in systemic lupus
erythematosus. Nat Clin Pract Rheumatol. 2006;2:562–9.
4. Bultink IE. Osteoporosis and fractures in systemic lupus erythematosus.
Arthritis Care Res. 2012;64:2–8.
5. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al.
Multilineage potential of adult human mesenchymal stem cells. Science.
1999;284:143–7.
6. Keating A. How do mesenchymal stromal cells suppress T cells? Cell Stem
Cell. 2008;2:106–8.
7. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stem
cells. Blood. 2007;110:3499–506.
8. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M,
et al. Treatment of severe acute graft-versus-host disease with third party
haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–41.
9. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Adipose-derived
mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory
and autoimmune responses. Gastroenterology. 2009;136:978–89.10. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, et al. Mesenchymal
stem cell transplantation reverses multi-organ dysfunction in systemic lupus
erythematosus mice and humans. Stem Cells. 2009;27:1421–32.
11. Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, et al. Umbilical cord
mesenchymal stem cell transplantation in severe and refractory systemic
lupus erythematosus. Arthritis Rheum. 2010;62:2467–75.
12. Wang D, Zhang H, Liang J, Li X, Feng X, Wang H, et al. Allogeneic
mesenchymal stem cell transplantation in severe and refractory systemic
lupus erythematosus: 4 years experience. Cell Transplant. 2013;22:2267–77.
13. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus
erythematosus. Adv Immunol. 1985;37:269–390.
14. Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y, et al. Transplantation of
human bone marrow mesenchymal stem cell ameliorates the autoimmune
pathogenesis in MRL/lpr mice. Cell Mol Immunol. 2008;5:417–24.
15. Gu Z, Akiyama K, Ma X, Zhang H, Feng X, Yao G, et al. Transplantation of
umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr
mice. Lupus. 2010;19:1502–14.
16. Yamaza T, Akiyama K, Chen C, Liu Y, Shi Y, Gronthos S, et al.
Immunomodulatory properties of stem cells from human exfoliated
deciduous teeth. Stem Cell Res Ther. 2010;1:5.
17. Ma L, Makino Y, Yamaza H, Akiyama K, Hoshino Y, Song G, et al.
Cryopreserved dental pulp tissues of exfoliated deciduous teeth is a feasible
stem cell resource for regenerative medicine. PLoS One. 2012;7, e51777.
18. Makino Y, Yamaza H, Akiyama K, Ma L, Hoshino Y, Nonaka K, et al. Immune
therapeutic potential of stem cells from human supernumerary teeth. J
Dent Res. 2013;92:609–15.
19. Tang Y, Xie H, Chen J, Geng L, Chen H, Li X, et al. Activated NF-κB in bone
marrow mesenchymal stem cells from systemic lupus erythematosus
patients inhibits osteogenic differentiation through downregulating Smad
signaling. Stem Cells Dev. 2013;22:668–78.
20. Friedenstein AJ. Stromal mechanisms of bone marrow: cloning in vitro and
retransplantation in vivo. Haematol Blood Transfus. 1980;25:19–29.
21. Yamaza T, Miura Y, Akiyama K, Bi Y, Sonoyama W, Gronthos S, et al. Mesenchymal
stem cell-mediated ectopic hematopoiesis alleviates aging-related phenotype in
immunocompromised mice. Blood. 2009;113:2595–604.
22. Dominici M, Le BK, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal
criteria for defining multipotent mesenchymal stromal cells. The International
Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.
23. Yamaza T, Miura Y, Bi Y, Liu Y, Akiyama K, Sonoyama W, et al. Pharmacologic
stem cell based intervention as a new approach to osteoporosis treatment
in rodents. PLoS One. 2008;3, e2615.
24. Yamaza T, Ren G, Akiyama K, Chen C, Shi Y, Shi S. Mouse mandible contains
distinctive mesenchymal stem cells. J Dent Res. 2011;90:317–24.
25. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling.
Emerging insights into the pathophysiology of osteoporosis. N Engl J Med.
1995;332:305–11.
26. Oshita K, Yamaoka K, Udagawa N, Fukuyo S, Sonomoto K, Maeshima K, et al.
Human mesenchymal stem cells inhibit osteoclastogenesis through
osteoprotegerin production. Arthritis Rheum. 2011;63:1658–67.
27. Varin A, Pontikoglou C, Labat E, Deschaseaux F, Sensebé L. CD200R/CD200
inhibits osteoclastogenesis: new mechanism of osteoclast control by
mesenchymal stem cells in human. PLoS One. 2013;8, e72831.
28. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, et al. Increased
interleukin-17 production in patients with systemic sclerosis. Arthritis
Rheum. 2000;43:2455–63.
29. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine
(IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with
systemic lupus erythematosus. Lupus. 2000;9:589–93.
30. Souto MI, Coelho A, Guo C, Mendonça LM, Pinheiro MF, Papi JA, et al. The
prevalence of low bone mineral density in Brazilian patients with systemic
lupus erythematosus and its relationship with the disease damage index
and other associated factors. J Clin Densitom. 2012;15:320–7.
31. Jacobs J, Korswagen LA, Schilder AM, van Tuyl LH, Dijkmans BA, Lems WF,
et al. Six-year follow-up study of bone mineral density in patients with
systemic lupus erythematosus. Osteoporos Int. 2013;24:1827–33.
32. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, et al. Health-related
quality of life in postmenopausal women with low BMD with or without prevalent
vertebral fractures. J Bone Miner Res. 2000;15:1384–92.
33. Hasserius R, Karlsson B, Jonsson B, Redlund-Johnell I, Johnell O. Long-term
morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly
– a 12 and 22 year follow-up of 257 patients. Calcif Tissue Int. 2005;76:235–42.
Ma et al. Stem Cell Research & Therapy  (2015) 6:104 Page 17 of 1734. Miller PD, Derman RJ. What is the best balance of benefits and risks among
anti-resorptive therapies for postmenopausal osteoporosis? Osteoporos Int.
2010;21:1793–802.
35. Sun LY, Zhang HY, Feng XB, Hou YY, Lu LW, Fan LM. Abnormality of bone
marrow-derived mesenchymal stem cells in patients with systemic lupus
erythematosus. Lupus. 2007;16:121–8.
36. Tang Y, Ma X, Zhang H, Gu Z, Hou Y, Gilkeson GS, et al. Gene expression
profile reveals abnormalities of multiple signaling pathways in
mesenchymal stem cell derived from patients with systemic lupus
erythematosus. Clin Dev Immunol. 2012;2012:826182.
37. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, et al.
Herpes virus Saimiri encodes a new cytokine, IL-17, which binds to a novel
cytokine receptor. Immunity. 1995;3:811–21.
38. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM,
et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage
distinct from the T helper type 1 and 2 lineages. Nat Immunol.
2005;6:1123–32.
39. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct
lineage of CD4 T cells regulates tissue inflammation by producing
interleukin 17. Nat Immunol. 2005;6:1133–41.
40. Okamoto K, Takayanagi H. Osteoclasts in arthritis and Th17 cell
development. Int Immunopharmacol. 2011;11:543–8.
41. Zhao R. Immune regulation of bone loss by Th17 cells in oestrogen-deficient
osteoporosis. Eur J Clin Invest. 2013;43:1195–202.
42. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al.
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent
stimulator of osteoclastogenesis. J Clin Invest. 1999;103:1345–52.
43. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al.
Th17 functions as an osteoclastogenic helper T cell subset that links T cell
activation and bone destruction. J Exp Med. 2006;203:2673–82.
44. Chang J, Liu F, Lee M, Wu B, Ting K, Zara JN, et al. NF-κB inhibits osteogenic
differentiation of mesenchymal stem cells by promoting β-catenin
degradation. Proc Natl Acad Sci U S A. 2013;110:9469–74.
45. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in
immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid
arthritis. Immunology. 2014;141:133–42.
46. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al.
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of
ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Lancet. 2013;382:1705–13.
47. Pöllinger B, Junt T, Metzler B, Walker UA, Tyndall A, Allard C, et al. Th17 cells,
not IL-17+ γδ T cells, drive arthritic bone destruction in mice and humans.
J Immunol. 2011;186:2602–12.
48. Tyagi AM, Mansoori MN, Srivastava K, Khan MP, Kureel J, Dixit M, et al. Enhanced
immunoprotective effects by anti-IL-17 antibody translates to improved skeletal
parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α
antibodies. J Bone Miner Res. 2014;29:1981–92.
49. van den Berg WB, McInnes IB. Th17 cells and IL-17 – a focus on
immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum.
2013;43:158–70.
50. Liu Y, Wang L, Kikuiri T, Akiyama K, Chen CD, Xu XT, et al. Mesenchymal
stem cell-based tissue regeneration is governed by recipient T lymphocytes
via IFN-Gamma and TNF-Alpha. Nat Med. 2011;17:1594–601.
51. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2013;9:11–5.
52. Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, et al. Mesenchymal-
stem-cell-induced immunoregulation involves FAS-ligand-FAS-mediated T
cell apoptosis. Cell Stem Cell. 2012;10:544–55.
53. Ghannam S, Pène J, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal
stem cells inhibit human Th17 cell differentiation and function and induce a
T regulatory cell phenotype. J Immunol. 2010;185:302–12.
54. Qu X, Liu X, Cheng K, Yang R, Zhao RC. Mesenchymal stem cells inhibit
Th17 cell differentiation by IL-10 secretion. Exp Hematol. 2012;40:761–70.
55. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells:
environmentally responsive therapeutics for regenerative medicine. Exp Mol
Med. 2013;45, e54.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
